anti-Cancer/testis Antigen 1B (CTAG1B) Anticorps

The protein encoded by CTAG1B is an antigen that is overexpressed in many cancers but that is also expressed in normal testis. De plus, nous expédions Cancer/testis Antigen 1B Kits (6) et et beaucoup plus de produits pour cette protéine.

afficher tous les anticorps Gène GeneID UniProt
CTAG1B 1485 P78358
Comment commander chez anticorps-enligne
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Commandez enligne

Top anti-Cancer/testis Antigen 1B Anticorps sur

Showing 10 out of 117 products:

Catalogue No. Reactivité Hôte Conjugué Application Images Quantité Livraison Prix Détails
Humain Lapin Inconjugué WB WB Suggested Anti-CTAG1B Antibody Titration: 1.0 ug/ml Positive Control: Fetal Stomach 100 μL 2 to 3 Days
Humain Lapin Inconjugué WB 100 μL 2 to 3 Days
Humain Chèvre Inconjugué ELISA, MA   100 μg 6 to 7 Days
Humain Souris Inconjugué IF, IHC, IHC (p), WB 100 μL 11 to 14 Days
Humain Souris Inconjugué IF, WB 100 μL 11 to 14 Days
Humain Souris Inconjugué IHC, IHC (p), WB 100 μL 11 to 14 Days
Humain Souris Inconjugué WB 100 μL 11 to 14 Days
Humain Lapin Inconjugué WB WB Image CTAG1B antibody detects CTAG1B protein by western blot analysis. Whole cell extracts (30 μg) was separated by 15% SDS-PAGE, and the membrane was blotted with CTAG1B antibody , diluted by 1:1000. 100 μL 3 to 4 Days
Humain Lapin Inconjugué IF (p), IHC (p), WB Lane 1: mouse testis lysates Lane 2: mouse lung lysates probed with Anti CTAG1B/Cancer/testis antigen 1 Polyclonal Antibody, Unconjugated (ABIN1385261) at 1:200 in 4 °C. Followed by conjugation to secondary antibody at 1:3000 90min in 37 °C. Predicted band 18kD. Observed band size: 18kD. 100 μL 3 to 7 Days
Humain Lapin Inconjugué IHC, IHC (p), WB Human Testis: Formalin-Fixed, Paraffin-Embedded (FFPE). This image was taken for the unconjugated form of this product. Other forms have not been tested. 100 μL 11 to 14 Days

anti-Cancer/testis Antigen 1B Anticorps mieux référencés

  1. Human Polyclonal CTAG1B Primary Antibody pour ELISA, MA - ABIN570720 : Shan, Lou, Xiao, Zhang, Sun, Gao, Cheng, Wu, Xu, Liu: A cancer/testis antigen microarray to screen autoantibody biomarkers of non-small cell lung cancer. dans Cancer letters 2012 (PubMed)

  2. Human Polyclonal CTAG1B Primary Antibody pour ELISA, MA - ABIN4265165 : Adams, ONeill, Nonaka, Hardin, Chiriboga, Siu, Cruz, Angiulli, Angiulli, Ritter, Holman, Shapiro, Berman, Berner, Shao, Manches, Pan, Venhaus, Hoffman, Jungbluth, Gnjatic, Old, Pavlick, Bhardwaj: Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. dans Journal of immunology (Baltimore, Md. : 1950) 2008 (PubMed)

Plus d’anticorps contre Cancer/testis Antigen 1B partenaires d’interaction

Human Cancer/testis Antigen 1B (CTAG1B) interaction partners

  1. TWIST1 and NY-ESO1 overexpression was associated with stage of progression and size of tumors in esophageal squamous cell carcinoma.

  2. MAGEA3 and CTAG1B are expressed in urothelial bladder neoplasms and may be useful in prognosis

  3. Twenty-eight out of 38 cancer specimens exhibited NY-ESO-1 protein expression, 2/38 showed a strong universal (4+) NY-ESO-1 staining, and 9/40 cancer lesions exhibited a strong (4+) staining for survivin.

  4. A significant association was found between AKAP4 gene expression and metastasis (P-value: 0.045), expression of the CTAG1B (NY-ESO-1) gene was not observed in our cases.

  5. In 22 melanoma patients with stage III lymph node metastasis, overall survival was significantly higher in the XAGE-1b and NY-ESO-1 double-negative group than in the other groups.

  6. The present results indicate the strong humoral immune response against NY-ESO-1 in natural human T-cell leukemia virus type 1 infection, irrespective of the clinical status.

  7. some autoantibodies, such as anti-MAGEA4, anti-CTAG1 or anti-TP53 and their combinations could possibly contribute to the development of cancer early detection tests (not necessarily restricted to gastric cancer) when being combined with other markers.

  8. High NY-ESO-1 expression is associated with Lung Cancer.

  9. Results support the potential utility of NY-ESO-1, PRAME, and MAGEA4 as targets for immunotherapy and as ancillary prognostic parameters in synovial sarcomas.

  10. Data suggest that only a small fraction of HLA-A*02:01- (HA)-binding ESO peptides are immunogenic, namely those that have high peptide-binding strength and peptide/HA complex stability. This study involved comparison of in silico-predicted and observed cytotoxic T-lymphocyte recognition of tumor antigen epitopes in melanoma patients and transgenic/knockout mice. (ESO = tumor antigen NY-ESO-1)

  11. These data demonstrate that MAGE-A1-, MAGE-A3-, and NY-ESO-1-specific T cells with antigen-specific cytotoxicity can be cultured from healthy donors and patient-derived cells making adoptive immunotherapy with these cytotoxic T lymphocyte feasible.

  12. Comparing the overall expression of CTAs, a decreased expression of all melanoma-associated antigens (MAGEs) post-treatment and a slightly increased expression of New York esophageal squamous cell carcinoma 1 (NY-ESO-1) was visible. The simultaneous cytoplasmic and nuclear expression of pan-MAGE or MAGE-A3/A4 correlated with reduced treatment-failure-free-survival (TFFS).

  13. MAGE-A is more highly expressed than NY-ESO-1 in a majority of human malignancies

  14. These cells were used to target a human lung cancer line that expressed NY-ESO-1.

  15. regulation of NY-ESO-1 processing by the ubiquitin receptors Rpn10 and Rpn13 as a well as by the standard and immunoproteasome is governed by non-canonical ubiquitination on non-lysine sites.

  16. CTAs (MAGE-A4, NY-ESO-1, MAGE-A10) were more likely expressed in patients with squamous cell carcinoma of the lung and when CTAs combined with CD133, they can be better prognostic factors.

  17. Among mesenchymal tumors, myxoid liposarcomas showed the highest positivity for NY-ESO-1 (88%), followed by synovial sarcomas (49%), myxofibrosarcomas (35%), and conventional chondrosarcomas (28%).

  18. High expression of NY-ESO-1 is associated with Triple-Negative Breast Cancer.

  19. NY-ESO-1 expression in melanoma was associated with tumor progression, including increased tumor thickness, and with reduced tumor infiltrating lymphocytes.

  20. NY-ESO-1 is expressed in esophageal adenocarcinomas, Barrett's metaplasia and normal tissues other than germ cells

Cancer/testis Antigen 1B (CTAG1B) profil antigène

Profil protéine

The protein encoded by this gene is an antigen that is overexpressed in many cancers but that is also expressed in normal testis. This gene is found in a duplicated region of the X-chromosome and therefore has a neighboring gene of identical sequence.

Gene names and symbols associated with CTAG1B

  • cancer/testis antigen 1B (CTAG1B) anticorps
  • CT6.1 anticorps
  • CTAG anticorps
  • CTAG1 anticorps
  • ESO1 anticorps
  • LAGE-2 anticorps
  • LAGE2B anticorps
  • NY-ESO-1 anticorps

Protein level used designations for CTAG1B

New York esophageal squamous cell carcinoma 1 , autoimmunogenic cancer/testis antigen NY-ESO-1 , cancer antigen 3 , cancer/testis antigen 1 , cancer/testis antigen 6.1 , l antigen family member 2

1485 Homo sapiens
Fournisseurs de qualité sélectionnés pour anti-Cancer/testis Antigen 1B (CTAG1B) Anticorps
Avez-vous cherché autre chose?